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Background. Meta-analysis is the systematic and quantitative synthesis of effect sizes and the exploration of their
diversity across different studies. Meta-analyses are increasingly applied to synthesize data from genome-wide association
(GWA) studies and from other teams that try to replicate the genetic variants that emerge from such investigations.
Between-study heterogeneity is important to document and may point to interesting leads. Methodology/Principal
Findings. To exemplify these issues, we used data from three GWA studies on type 2 diabetes and their replication
efforts where meta-analyses of all data using fixed effects methods (not incorporating between-study heterogeneity)
have already been published. We considered 11 polymorphisms that at least one of the three teams has suggested as
susceptibility loci for type 2 diabetes. The I
2 inconsistency metric (measuring the amount of heterogeneity not due to
chance) was different from 0 (no detectable heterogeneity) for 6 of the 11 genetic variants; inconsistency was moderate
to very large (I
2=32–77%) for 5 of them. For these 5 polymorphisms, random effects calculations incorporating between-
study heterogeneity revealed more conservative p-values for the summary effects compared with the fixed effects
calculations. These 5 associations were perused in detail to highlight potential explanations for between-study
heterogeneity. These include identification of a marker for a correlated phenotype (e.g. FTO rs8050136 being associated
with type 2 diabetes through its effect on obesity); differential linkage disequilibrium across studies of the identified
genetic markers with the respective culprit polymorphisms (e.g., possibly the case for CDKAL1 polymorphisms or for
rs9300039 and markers in linkage disequilibrium, as shown by additional studies); and potential bias. Results were largely
similar, when we treated the discovery and replication data from each GWA investigation as separate studies.
Significance. Between-study heterogeneity is useful to document in the synthesis of data from GWA investigations and
can offer valuable insights for further clarification of gene-disease associations.
Citation: Ioannidis JPA, Patsopoulos NA, Evangelou E (2007) Heterogeneity in Meta-Analyses of Genome-Wide Association Investigations. PLoS
ONE 2(9): e841. doi:10.1371/journal.pone.0000841
INTRODUCTION
Meta-analysis entails the combination of different studies or
datasets on the same research question and meta-analytic methods
have been used across many different scientific disciplines [1,2].
Early applications of meta-analysis in the 1970s and 1980s
proposed that a major gain from these methods was the ability to
improve power and obtain more definitive summary results by
combining several small studies [3]. However, it soon became
evident that simply focusing on summary effects could be
misleading. For epidemiological applications in particular, a major
threat is that the precision derived from combining data may be
spurious, especially if the combined studies and datasets have
considerable dissimilarities [4]. It is well appreciated now that
besides estimating summary effects, estimation and, if possible,
explanation, of the between-study heterogeneity is a very impor-
tant goal for meta-analysis [5].
One of the most rapidly growing applications of meta-analysis
is in genetic epidemiology [6–8]. Meta-analysis is becoming
standard practice for publications of genome-wide association
studies that search for common genetic variants regulating
complex traits and disease risk. A torrent of such studies have
started appearing in the most prestigious journals with major
prospects for the delineation of the genetic risk factors underlying
the most common diseases and traits [9]. The results of the
genome-wide associations are typically combined with the results
of additional replication studies on the most promising variants;
occasionally results from other genome-wide investigations are
also included in meta-analytic calculations [10–13]. However,
these early applications of meta-analyses on such datasets have
not accommodated between-study heterogeneity in the data
synthesis. In the presence of between-study heterogeneity in the
genetic effects, there may be important implications for the
interpretation of the results.
We exemplify this issue for meta-analyses of genome-wide
association and replication data on postulated genetic variants
conferring susceptibility to type 2 diabetes [10–13]. We have
revisited these data to examine the extent of between-study
inconsistency, whether summary results may differ with consider-
ation of between-study heterogeneity, and what insights may be
gleaned from the presence of between-study heterogeneity in this
setting.
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Fixed versus random effects
Data were combined in the original Science publications [10–13]
using a fixed effects (Mantel-Haenszel) model. Fixed effects assume
that the genetic effects are the same across the combined
investigations and all differences are due to chance [1,2]. While
this assumption is true occasionally, it may not be generalizable to
all genetic associations. Genetic effects may vary across different
populations for various reasons, including both genuine differences
and differential biases and errors across studies [14,15]. In meta-
analyses, fixed effects may give more narrow confidence intervals
and more impressively low p-values compared with models that
accommodate potential diversity of effects (heterogeneity)
[1,2,5,16,17]. We have re-analyzed the meta-analyses of the three
teams with random effects calculations [1,2]. Random effects
calculations assume that due to genuine differences and or
different biases, the estimates of the genetic effects may vary
across different investigations. Random effects thus try to estimate
the population average and the extent of dispersion in these
different effect sizes. The presented random effects calculations use
the DerSimonian and Laird estimator of the between-study
variance [18].
Heterogeneity metrics
Different metrics have been proposed for testing the presence and
measuring the amount of between-study heterogeneity. Cochran’s Q
statistic [19] is provided by Q=S wi
F (di2d
F
+)
2 where d
F
+ is the
summary effect size by fixed effects, di are the study-specific effect
sizes and wi
F is the weight of each study (based on Mantel-
Haenszel methods). The statistic follows a x
2 distribution with k-1
degrees of freedom (k is the number of studies or datasets
combined), and it is typically considered significant at the a=0.10
level. The original Science publications used this test to document
whether there is or not between-study heterogeneity. However,
this test is grossly underpowered, when there are very few studies.
Also with small studies, the confidence intervals of each one may
be very large, so the same problem of lack of power may still
persist. Of note, Q is used in the estimation of the between-study
variance, given by t2~
Q{(k{1)
P
wi{
P
w2
i P
wi
. The ratio of t over the
effect size conveys the extent of variability (between-study standard
deviation) as compared with the effect size.
Another useful metric is the I
2. This metric is independent of the
number of studies and can be compared across meta-analyses with
different number of studies and metrics [16,17]. I
2 is given by the
formula I2~
Q{(k{1)
Q
|100% and it is a measure of the
percentage of total variation across studies due to heterogeneity
beyond chance. Therefore, I
2 takes values between 0–100%.
Values over 50% indicate large heterogeneity. I
2 can be estimated
along with its confidence intervals and the confidence intervals are
wider when a meta-analysis includes few studies [20]. The
confidence intervals for I
2 can be calculated with different
methods (described in detail in [17]). Confidence intervals usually
can be very large, unless many studies are available, and this is
another indication that one has to be cautious about claiming
homogeneity (even when I
2 is zero). Overall, there can be large
uncertainty in a meta-analysis about the presence or not and the
extent of between-study heterogeneity. Strong inferences about
heterogeneity or lack thereof may be a common misconception
when limited data are available.
Datasets
Data are derived from the original Science publications of 3 GWA
investigations and their replication efforts (advance online publica-
tions in Science on April 26, 2007 [10,11,13]). These investigations
were conducted by the Finland-United States Investigation on
NIDDM Genetics (FUSION) team, the Diabetes Genetics Initiative,
and the Wellcome Trust Case-Control Consortium. Extensive details
of the design and populations of these investigations have been
presented in the original publications [10,11,13]. In brief, all three
publications used a discovery dataset where GWA evaluation was
performed on Illumina or Affymetrix chips and promising genetic
variants were further tested for replication in large replication
datasets. The number of polymorphisms tested in the discovery phase
of each investigation were 317503, 500568, and 499032, respectively
and the number of polymorphisms that were considered to have data
suitable for analyses were 315635, 386731, and 393453, respectively.
The FUSION investigation used 1161 cases and 1174 controls in the
discovery phase and 1215 cases and 1258 controls in the replication
phase. The Diabetes Genetics Initiative investigation used 1464 cases
and 1467 controls in the discovery phase and 5065 cases and 5785
controls in the replication phase. The Wellcome Trust Case control
Consortium used 1924 cases and 2938 controls in the discoveryphase
and 3757 cases and 5346 controls in the replication phase.
In order to identify which of the many promising polymorphisms
were eventually most important as susceptibility loci for type 2
diabetes, the three investigations performed a meta-analysis of their
data. All three publications eventually reported tables of ‘‘con-
firmed’’ susceptibility loci of type 2 diabetes. We examined all 11
genetic variants that have been listed in these tables as ‘‘confirmed’’
loci. Eight of those variants appear in the ‘‘confirmed’’ lists of all 3
publications; while rs9300039 is listed in the table of confirmed loci
by FUSION investigators only [10]; rs564398 (a second marker in
the CDKN2B gene besides the rs10811661 that is considered
confirmed byall three publications)islistedinthe tableofconfirmed
loci by the Wellcome Trust Case Control Consortium investigators
only [13]; and FTO rs8050136 (an obesity risk variant, as discussed
below) is listed in the table of confirmed loci by the Wellcome Trust
Case Control Consortium and FUSION only [10,13]. These
differences reflect simply minor differences in interpretation and
listing of the same results between the three teams of investigators.
We treated each GWA analysis and its replication efforts as one
study, as in the original Science publications. Therefore, three
studies were analyzed for between-study heterogeneity and meta-
analysis was performed with random effects on these 3 estimates,
as described above. In a sensitivity analysis, for each GWA
investigation, we treated the GWA discovery data as a separate
study from the GWA replication data. Thus in the sensitivity
analysis, between-study heterogeneity was estimated and random
effects meta-analysis was performed considering a maximum 6
estimates. Some markers had not been pursued for testing in the
replication phase of all 3 GWA investigations, thus they are
represented by 5 or 4 estimates in the sensitivity meta-analysis. We
should caution that even with this further split, each of the
estimates may still be composed on several sub-studies. For
example, the replication efforts may be comprised on many
smaller teams and their data have already been synthesized (again
using fixed effects assumptions), but separate data for these sub-
studies are not consistently available. In some cases, the pieces
would be even impossible to separate, as for example when the
group of cases was composed of many smaller samples recruited
from different places, while the control group was more uniformly
recruited. By accepting that the sub-studies are sufficiently
homogeneous, the estimates of between-study heterogeneity that
Genome-Wide Associations
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heterogeneity that may exist in the data.
For each of the polymorphisms where we identified moderate or
larger estimates of between-study heterogeneity (I
2$25%), we
discuss the potential insight that may be offered by this
heterogeneity and how it may affect or not the interpretation of
the results. We also retrieved additional studies that have been
published on the same or linked polymorphisms as of May 12,
2007 on type 2 diabetes or related phenotypes so as to consider
potentially additional evidence from other relevant studies in the
interpretation of the results. Additional studies were identified by
PubMed searches using ‘‘diabetes’’ and ‘‘association’’ limited to
the year 2007. Relevant additional data that were available were
also incorporated into updated random effects meta-analyses.
Software
All calculations have been performed in Intercooled STATA 8.2
(College Station, TX) using the metan module. The presented
confidence intervals for I
2 are obtained using the non-central chi-
square distribution-based method [17] using the heterogi STATA
module. P-values are two-tailed.
RESULTS
Main analyses
As shown (Table 1), the I
2 metric was different from 0 (no
detectable heterogeneity) for 6 of the 11 genetic variants.
Inconsistency of the genetic effects across the three investigations
was very large (I
2$75%) for rs9300039 and FTO rs8050136,
moderate (I
2 between 25–50%) for PPARG rs1801282, CDKAL1
rs10946398 and SLC30A8 rs13266634, and low (I
2 up to 25%) for
IGF2BP2 rs4402960. In fact the upper 95% CI of I
2 extended up
to very high levels of inconsistency (73–91%) for all 11
polymorphisms; thus, between-study heterogeneity in the genetic
effects cannot be confidently excluded for any of them.
Conversely, even when the I
2 estimate is high, the 95% confidence
intervals typically do not exclude the possibility of homogeneity. I
2
is an indicator, not absolute proof of homo- or heterogeneity.
The heterogeneity test (Cochran’s Q statistic) was formally
statistically significant for the FTO variant (p=0.014) and the
rs9300039 marker (p=0.018). As Q is grossly underpowered with
only 3 studies, lack of nominal statistical significance for
heterogeneity in the other polymorphisms does not prove
homogeneity of effects. Of interest, the two loci with highest-
between study heterogeneity were not unanimously proposed as
‘‘conformed’’ susceptibility loci by all 3 GWA investigations.
The summary point estimates (odds ratios) are practically not
different with random versus fixed effects with 8 of the 11 pairs of
estimates being identical to the second decimal point (Table 1).
However, for the 5 variants with moderate to very large between-
study heterogeneity, the 95% confidence intervals expand sub-
stantially with random effects calculations and p-values do not
satisfy criteria for genome-wide significance (p,10
27) based on
these data alone.
Sensitivity analyses
Sensitivity analysesconsidering thediscoveryand replication data of
each GWA investigation as separate data yielded largely similar
results as the main analysis (Table 2).Minor differenceswereseen in
the exact estimates of I
2 but the categorization of the amount of
between-study heterogeneity was largely similar. With this analysis,
there was now also low heterogeneity (I
2,25%) for the HHEX
rs5015480-rs1111875 effect, while I
2 became 0 for SLC30A8
rs13266634. Again the confidence intervals of I
2 were very large,
the upper limit being between 61 and 86% for the various markers.
Examination of markers with moderate or larger
between-study heterogeneity
Examination of the 5 polymorphisms that had moderate or larger
between-study heterogeneity in their effect sizes shows that
detection of between-study heterogeneity can offer useful insights.
Table 1. Between-study heterogeneity and random versus fixed effects calculations for polymorphisms that were considered
‘‘confirmed’’
..................................................................................................................................................
GENE Polymorphism Q (p) I
2 (95% CI)
Random effects OR
(95% CI)
Fixed effects OR
(95% CI)
Random effects
p-value
Fixed effects
p-value
— rs9300039
a 7.98 (0.019) 75% (0–90) 1.25 (1.04–1.50) 1.25 (1.15–1.37) 0.015 4.3610-7
FTO rs8050136 8.62 (0.013) 77% (0–91) 1.13 (1.02–1.25) 1.17 (1.12–1.22) 0.015 1.3610
212
PPARG rs1801282 3.80 (0.15) 47% (0–84) 1.16 (1.07–1.25) 1.14 (1.08–1.20) 0.0003 1.7610
26
CDKAL1 rs10946398
b 3.73 (0.16) 46% (0–84) 1.12 (1.07–1.17) 1.12 (1.08–1.16) 3.2610
26 4.1610
211
SLC30A8 rs13266634 2.92 (0.23) 32% (0–81) 1.12 (1.07–1.18) 1.12 (1.07–1.16) 8.7610
26 5.3610
28
CDKN2B rs564398 1.48 (0.48) 0% (0–73) 1.12 (1.07–1.17) 1.12 (1.07–1.17) 1.2610
27 1.2610
27
HHEX rs5015480–
rs1111875
0.45 (0.80) 0% (0–73) 1.13 (1.08–1.17) 1.13 (1.08–1.17) 5.7610
210 5.7610
210
KCNJ11 rs5215
c 0.56 (0.76) 0% (0–73) 1.14 (1.10–1.19) 1.14 (1.10–1.19) 5610
211 5610
211
IGF2BP2 rs4402960 2.65 (0.27) 25% (0–79) 1.15 (1.10–1.19) 1.14 (1.10–1.18) 6.5610
212 8.6610
216
CDKN2B rs10811661 0.03 (0.99) 0% (0–73) 1.20 (1.14–1.25) 1.20 (1.14–1.25) 7.8610
215 7.8610
215
TCF7L2 rs7901695
d 0.24 (0.89) 0% (0–73) 1.37 (1.31–1.43) 1.37 (1.31–1.43) 1.0610
248 1.0610
248
Additive models are presented, as in the main analyses of the original papers. Fixed effects calculations are Mantel-Haenszel estimates as in the original papers. Random
effects calculations use the DerSimonian and Laird estimators for the between-study variance.
CI: confidence interval; OR: odds ratio
amulti-marker tag in DGI and rs1514823 in the UK study
brs7754840 in FUSION
crs5219 in FUSION and DGI
drs7903146 in FUSION and DGI
doi:10.1371/journal.pone.0000841.t001
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that was listed by the FUSION investigators as a confirmed
susceptibility locus for type 2 diabetes [10]. The random effects
summary odds ratio yielded a mere p=0.015, as compared with
p=4.3610
27 by Mantel-Haenszel calculations, and there was
very large between-study heterogeneity (75%). Heterogeneity
might reflect in part the different tag polymorphisms used in the
other two GWA investigations [11,13]. Even so, the evidence
remains very weak. Fine mapping and more extensive data would
be required for this locus before a concrete claim can be made that
it confers susceptibility to type 2 diabetes.
For FTO rs8050136, the random effects summary odds ratio
yielded also a mere p=0.015, as compared with the impressive
Mantel-Haenszel p=1.3610
212 originally reported. Between-
study heterogeneity is also very large (77%). Heterogeneity is
visible even with plain data inspection, especially for the Wellcome
Trust Case Control Consortium vs. Diabetes Genetics Initiative
results (figure 1). Consistent with this strong signal of between-
study heterogeneity, the Wellcome Trust investigators have indeed
found that this variant is a susceptibility marker for increased body
mass index and obesity [12]. Type 2 diabetes susceptibility may be
mediated through the effect on body mass index and is not an
independent effect that should have been seen consistently in all
populations. The observed heterogeneity for type 2 diabetes
association is also explained by the study design of the 3 GWA
investigations. The Diabetes Genetics Initiative used a tightly
matched case-control sample in the discovery phase, where cases
and controls had been matched for body mass index [11] and thus
it is not surprising that there was no residual effect of this FTO
variant on the risk of type 2 diabetes.
For the novel proposed CDKAL1 rs10946398 association,
additional data were recently published from deCODE and
affiliated investigators in Nature Genetics [21] who proposed
a different polymorphism in the same gene (rs7756992) as a T2D
marker. The r
2 for these two markers was only 0.67 in Caucasians,
but 4 other CDKLA1 polymorphisms in the deCODE data [21]
have r
2=1 with rs10946398. Including the deCODE data for the
nearest one (rs7774594) in the meta-analysis calculations, the
summary odds ratio became 1.13 (95% CI, 1.08–1.18) with
p=2.2610
27. Moderate between-study heterogeneity persisted
(I
2=43%). In the deCODE presented results for rs7756992 (ref.
13), we estimated very large between-population heterogeneity in
the genetic effects between three different racial descent popula-
tions (I
2=76%). Compared with Caucasians, the correlation
between rs10946398 (or rs7774594) and rs7756992 was much
weaker in Africans (r
2=0.35). In Africans, deCODE investigators
noticed that rs7756992 showed no association effect (odds ratio
1.02). The very large heterogeneity in genetic effects for rs7756992
and the moderate heterogeneity for rs10946398 might suggest that
neither polymorphism is the true culprit; the culprit may be more
consistently correlated (even in Africans) with rs10946398 than
with rs7756992.
For SLC30A8 rs13266634 data were also available from the
deCODE investigation [21] and from another study by Sladek et
al. [22]. Including these data, we got a random effects odds ratio of
1.15 (95% 1.10–1.19) with p=3.5610
213. Some low heterogene-
ity persisted (I
2=21%). While SLC30A8 rs13266634 amply passed
genome-wide significance when additional data were considered,
the presence of between-study heterogeneity suggests the true
culprit variant may still be elusive.
The same may apply to PPARG rs1801282, which had been
extensively studied in the past (before the GWA investigations) in
many other studies, again with clear association in the summary
effect, but with some co-existing between-study heterogeneity [23].
Efforts to identify the true functional culprit variants of PPARG (if
different from rs1801282) are ongoing. By comparison, the other
two variants that been already known and extensively studied
before the 3 GWA investigations (KCNJ11 rs5215 and TCF7L2
rs7901695) have I
2=0 in both the main and sensitivity meta-
analyses.
DISCUSSION
In a re-analysis of the data from 3 GWA studies on type 2 diabetes,
we found that for 5 of the 11 genetic variants that are considered
‘‘confirmed’’ susceptibility loci for type 2 diabetes there was still
moderate to very large between-study heterogeneity across the
different GWA investigations. Given the between-study heteroge-
neity, the level of statistical significance was more conservative
Table 2. Between-study heterogeneity and random versus fixed effects calculations for polymorphisms that were considered
‘‘confirmed’’ in sensitivity analyses considering the discovery and replication data of each GWA as a separate study.
..................................................................................................................................................
GENE Polymorphism Q (df)
a [p] I
2 (95% CI)
Random effects OR
(95% CI)
Fixed effects
OR (95% CI)
Random effects
p-value
Fixed effects
p-value
— rs9300039 8.38 (3) [0.039] 64% (0–86) 1.29 (1.11–1.50) 1.26 (1.15–1.37) 0.001 2.8610
28
FTO rs8050136 12.98 (4) [0.011] 69% (0–86) 1.15 (1.06–1.25) 1.17 (1.12–1.23) 0.001 2.5610
212
PPARG rs1801282 6.93 (4) [0.14) 42% (0–76) 1.14 (1.06–1.23) 1.13 (1.08–1.20) 0.0007 3.4610
26
CDKAL1 rs10946398 8.76 (5) [0.12] 43% (0–76) 1.13 (1.07–1.18) 1.12 (1.08–1.15) 1.2610
26 1.9610
210
SLC30A8 rs13266634 3.17 (5) [0.67] 0 (0–61) 1.13 (1.08–1.17) 1.13 (1.08–1.17) 4.1610
29 4.1610
29
CDKN2B rs564398 3.62 (4) [0.46] 0% (0–64) 1.11 (1.06–1.15) 1.11 (1.06–1.15) 5.8610
27 5.8610
27
HHEX rs5015480–
rs1111875
6.20 (5) [0.29] 19% (0–68) 1.13 (1.08–1.17) 1.12 (1.08–1.17) 2.2610
28 3.2610
210
KCNJ11 rs5215 3.50 (4) [0.48] 0% (0–64) 1.14 (1.09–1.18) 1.14 (1.09–1.18) 9610
211 9610
211
IGF2BP2 rs4402960 7.08 (5) [0.21] 29% (0–71) 1.15 (1.10–1.20) 1.15 (1.11–1.19) 2.9610
210 1.1610
215
CDKN2B rs10811661 4.15 (5) [0.53] 0% (0–61) 1.20 (1.15–1.25) 1.20 (1.15–1.25) 2.7610
215 2.7610
215
TCF7L2 rs7901695 1.31 (4) [0.86] 0% (0–64) 1.37 (1.32–1.43) 1.37 (1.32–1.43) 1.0610
248 1.0610
248
CI: confidence interval; OR: odds ratio
adf=degrees of freedom; not all markers were tested by all 3 investigations in their replication efforts, thus even with splitting the discovery and replication phases,
there are fewer than 6 datasets (df=5) for some variants.
doi:10.1371/journal.pone.0000841.t002
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PLoS ONE | www.plosone.org 4 September 2007 | Issue 9 | e841with random effects calculations. Further examination of these
potentially heterogeneous associations suggested possible explana-
tions for the observed inconsistency. In several cases, this probably
reflected either the fact that the identified marker was not the
culprit polymorphism, but had a different linkage disequilibrium
pattern with the culprit polymorphism across different studies. In
the case of FTO, it probably reflected the fact it was associated
with type 2 diabetes through its effect on the correlated phenotype
of obesity; the phenotype correlation varied across different
studies. Additional possibilities may need to be considered also
for the heterogeneity, as discussed below. Conversely, we should
caution that homogeneity of effects for the other 6 variants
provides limited information on whether a causative locus has
been identified. Lack of heterogeneity is not proof of causality.
Overall, detection of heterogeneity is very useful. Some
polymorphisms are shown to reach genome-wide statistical
significance by fixed effects calculations, but not by random
effects calculations due to large between-study heterogeneity. In
these cases, priority should be given to the consideration of other,
correlated phenotypes and fine mapping for identifying linked,
true culprit polymorphisms that yield less heterogeneous associa-
tion signals. These situations are likely to be very common in the
GWA setting. Tag markers are not selected based on ‘‘candidate
gene variant’’ considerations [24]. Thus it is more likely that one
may hit upon a variant that is a linked marker rather than hit
directly upon the culprit causative variant. Markers will often have
variable linkage disequilibrium across different populations. This
will result in heterogeneous genetic effects across studies.
Correlated phenotypes are also a major issue. Many common
diseases and traits (e.g. diabetes, myocardial infarction, obesity,
hypertension, metabolic syndrome) are modestly or even highly
correlated. Inconsistent susceptibility signals for one of them may
reflect consistent associations with another correlated phenotype.
Moreover,mostcommondiseasesthatareassumedtohaveacomplex
genetic background are probably a complex mix of different
phenotypes in termsof their molecular pathogenesis. Genetic variants
may have specific molecular functional effects that cumulatively build
a complex clinical phenotype. However, depending on their
molecular background, the relative representation of these pheno-
types may vary in different people and populations with seeminglythe
same clinical disease. The case definition of this broad clinical
phenotype may not do justice to the underlying molecular
complexity. Molecular and clinical phenotypes may exhibit some
correlation pattern, but this may vary in different sub-populations
depending on the presence of other gene variants. Again, statistical
heterogeneity may offer a window to this complexity.
Another possibility is bias. Incorporating between-study hetero-
geneity in the summary calculations has the advantage to penalize
associations where results are inconsistent across studies due to
population-specific biases and gives higher ranks to the consistent
associations [25]. The 3 GWA investigations on type 2 diabetes
paid meticulous attention to methodological detail and their design
was exemplary. Careful genotyping controls were set and
population stratification was controlled with principal component
analysis [26]. Nevertheless, minute biases affecting particular
polymorphisms with minute odds ratios around 1.12 cannot be
excluded. Even if some major systematic errors (e.g. population
stratification, genotyping error, phenotype misclassification) are
controlled, not all biases are foreseeable. Moreover, minimized
average biases do not exclude much larger differential biases for
a few polymorphisms. P-values for testing the observed genetic
effects against the null effect hypothesis account for random, not
systematic, error.
Another potential reason for heterogeneity is the winner’s curse,
a manifestation of chance and regression-to-the-mean, especially
under circumstances of multiple testing with limited power. The
first study that claims an association that passes a very demanding
required significance threshold may exhibit a genetic effect that is
larger than the true average effect of this association.
Finally, another possibility is gene-environment interactions
(e.g. as proposed for rs1801282 and low physical activity [27]) with
differential non-genetic environmental exposures across different
populations. Moreover, genuine genetic heterogeneity in effect
sizes across different ethnic backgrounds and population-specific
gene-gene epistatic effects are sometimes postulated. However,
interaction effects (effect modification) may require huge studies to
Figure 1. Meta-analysis of the FTO rs8050136 variant in terms of its association with type 2 diabetes across three GWA investigations. Each
investigation is shown by the point estimate of the odds ratio and 95% confidence intervals. Also shown is the diamond of the summary effect by
fixed and random effects calculations.
doi:10.1371/journal.pone.0000841.g001
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have been put together in the genetics of type 2 diabetes.
We should stress that estimation of between-study heterogeneity
carries considerable uncertainty and in the typical situation it
would be impossible to have a large number of large studies to
fully power detection and accurate estimation of heterogeneity.
Moreover, breaking down populations to sub-studies may
sometimes lead to loss of estimated between-study heterogeneity,
if the sub-studies are small and their confidence intervals of effects
are very large. However, this would offer misleading reassurance
that no heterogeneity exists. While the number of datasets may
increase by such splitting, each dataset would have very limited,
inconclusive information about the magnitude of the effect and it
would again be very difficult to show the between-study
heterogeneity, even if present.
In general, when between-study heterogeneity is demonstrated
or cannot be excluded, random effects models have been accepted
as the default across different applications of meta-analysis and this
should be accepted also for GWA investigations [1,2,5]. Fixed
effects may sometimes result into misleading inferences. In the
presence of heterogeneity, the main assumption of fixed effects is
violated and their application is inappropriate. However, a caveat
for random effects is that they tend to diminish the difference in
the relative weighting of small vs. larger studies. This is a drawback
in situations where small studies may suffer more from errors or
biases than larger studies. Disproportionate weighting of the biased
small studies would then lead to erroneous results. This situation
may typically arise when the data to be synthesized have been
collected retrospectively from published information and publica-
tion bias is operating in the field [27]. Small studies may have been
published preferentially when they show significant results while
the evidence from larger studies may be available regardless of the
results. Thus the total available evidence from larger studies may
be more unbiased, even if single larger studies may not necessarily
be more unbiased than single smaller studies.
While this bias is a concern for retrospective meta-analyses, it
should not be an issue for a prospective collaborative GWA
investigation performed within a consortium of investigators. In
this setting, there is no reason why investigators would select to
include in the calculations only the most impressive results.
However, a particular threat for the credibility of GWA results
occurs, if several GWA investigations are performed and results
are made available only for the most significant p-values in each
GWA investigation. While this deficit will hopefully be remedied
by quick release of genome-wide data in the future, the majority of
studies have not done so yet.
We should also mention that there are different models that can
incorporate between-study heterogeneity in the calculations. We
used a conservative approach, the DerSimonian and Laird model,
that is the most frequently used random effects model in the
literature. Other fully Bayesian approaches may also be used [29],
including hierarchical Bayesian models. Some of these models may
incorporate also other parameters such as minor deviations from
Hardy-Weinberg equilibrium in the observed genotyping data
[30]. These models usually tend to give even larger uncertainty
and they widen the 95% credibility intervals of the estimates [29].
In all, heterogeneity is a useful aspect of the data, rather than
a nuisance, as it can often point to leads that can clarify better the
nature of postulated associations in the context of meta-analysis
[31]. Heterogeneity should not be ignored and should be carefully
factored in the interpretation of emerging genetic associations
from GWA studies. Heterogeneity has implications also for the
epidemiological design of GWA studies and their replication
efforts. Consistency in the definition of phenotypes and meticulous
attention to quality control in genotyping and avoidance of
population stratification is warranted, so as to avoid heterogeneity
due to bias. However, heterogeneity due to genuine differences
should not be avoided. Thus one should encourage diversity in
secondary aspects of the study design across studies, such as the use
of matching or not for other population characteristics, and
targeting of populations of diverse racial descent with different
linkage disequilibrium patterns. Finally, proper evaluation of
between-study heterogeneity would ideally require complete and
transparent individual-level information on genotype results from
all conducted GWA investigations. Ensuring full public data
availability would enhance the credibility of GWA evidence.
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